Publications by authors named "Mei Shimada"
Background: Ovarian cancer remains a formidable challenge in oncology, necessitating innovative therapeutic approaches. Claudin-6 (CLDN6), a member of the tight junction molecule CLDN family, exhibits negligible expression in healthy tissues but displays aberrant upregulation in various malignancies, including ovarian cancer. Although several therapeutic modalities targeting CLDN6 are currently under investigation, there is still a need for more potent therapeutic options.
View Article and Find Full Text PDFArticle Synopsis
- Overcoming resistance to immune checkpoint inhibitors is critical for treating non-small-cell lung cancer (NSCLC), which includes different molecular subtypes with distinct immune landscapes.
- The study identifies three adenocarcinoma subtypes (TRU, PP, PI) and their immune responses, finding that the PI subtype has a stronger immune activation while the PP subtype shows features that suppress the immune response.
- Understanding these immune characteristics can guide personalized treatment strategies, suggesting that immune checkpoint inhibitors may work well for the PI subtype and that targeting glycolysis could help improve the immune response in the PP subtype.
Unlabelled: Resistance to immune checkpoint blockade remains challenging in patients with non-small cell lung cancer (NSCLC). Tumor-infiltrating leukocyte (TIL) quantity, composition, and activation status profoundly influence responsiveness to cancer immunotherapy. This study examined the immune landscape in the NSCLC tumor microenvironment by analyzing TIL profiles of 281 fresh resected NSCLC tissues.
View Article and Find Full Text PDF